npj Breast Cancer

SEP 4, 2026 · JOURNAL ARTICLE

Benmelstobart plus antiangiogenic therapy vs chemotherapy for metastatic triple-negative breast cancer: phase III trial

npj Breast Cancer

Underpowered trial prematurely stopped at 46% of planned enrollment with non-significant primary endpoint; efficacy analyses explicitly stated as exploratory, requiring cautious interpretation.

AUG 12, 2026 · JOURNAL ARTICLE

Quantitative and qualitative patient-reported analysis of misdiagnosis and/or late diagnosis of metastatic lobular cancer

npj Breast Cancer

A patient-reported survey study using descriptive statistics without a control group or comparator; establishes prevalence of reported misdiagnosis in metastatic invasive lobular cancer but lacks analytical rigor and hard clinical outcomes.

AUG 8, 2026 · JOURNAL ARTICLE

“Molecular divergence shapes lung- and liver-preferential metastasis in HER2-positive breast cancer”

npj Breast Cancer

A mechanistic study establishing novel murine models of organ-preferential metastasis with supporting transcriptomic validation in clinical cohorts, but lacking clinical trial evidence of therapeutic efficacy.